Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model
Status:
Completed
Trial end date:
2021-06-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the chemoprophylactic activity and
dose-exposure-response relationship of single oral dose of M5717 administered after direct
intravenous inoculation (DVI) of Plasmodium falciparum sporozoite (PfSPZ) challenge in
healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany